Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | L. Hwang, W. Wang, S. Qazi, K. Ng, O. D’cruz, V. Trieu | ||||||||||||
Title | L-8 as a pharmacodynamic biomarker for TGF-b2 antisense (trabedersen) therapy: Results of a phase II trial | ||||||||||||
|
|||||||||||||
URL | https://www.annalsofoncology.org/article/S0923-7534(20)37613-4/fulltext | ||||||||||||
Abstract Text | Background: In a Phase I/II study of Trabedersen (OT-101), a phosphorothioate antisense specific for human TGF- b2 mRNA, patients with advanced pancreatic cancer (PAC) treated in the 2nd-line and beyond exhibited improved overall survival (OS) when OT-101 was followed with chemotherapy. Here, we examined the association between plasma levels of cyto-/chemokines and OS outcomes to identify potential biomarkers for improved OS. Methods: 37 PAC patients were treated with continuous IV infusion in escalating doses of 2 treatment schedules (7-days-on, 7-days-off and 4-days-on, 10-days-off). Plasma levels of 31 cyto-/chemokines were measured at 8 separate time points over 3 cycles of OT-101 treatment (140 mg/m2 /day, 4-days-on, 10-days-off). Standardized maximum levels of individual cyto-/chemokines on Day 2 were subtracted from levels on Day 5 of each cycle of treatment and correlated with log10 transformed OS values. Feedback interactions with PK parameters were also investigated utilizing an ANCOVA model. Results: A median OS of 14.5 months and 2.6 months was observed for 2nd-line patients treated with and without subsequent chemotherapies, respectively (p ¼ 0.0009). Increasing difference of IL-8 levels at Day 2 vs Day 5 was positively correlated with OS (R2 ¼ 0.58, P ¼ 0.0066). Stratifying for patients with and without chemo, R2 increased to 0.99 and 0.77 respectively. Similar results were observed for IL-15, with R2 ¼ 0.93 in patients with chemo and R2 ¼ 0.50 in those without. ANCOVA models for two PK parameters exhibited significant model fits (F3,7 ¼ 7.89, P ¼ 0.012 for Simulated Vz Mean; F3,7 ¼ 8.18, P ¼ 0.011 for Simulated Cl Mean) and the interaction effects resulted in lower p-values for the correlation of OS vs IL-8 levels. Conclusions: Increasing peak levels of IL-8 and IL-15 response on Day 2 of OT-101 treatment correlated with OS in PAC patients. This correlation with OS was evident regardless of subsequent chemotherapy or not indicating spikes in IL-8 and IL-15 as potential biomarkers for OT-101 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|